Analyst Ratings For NASDAQ:LPTX – Leap Therapeutics (NASDAQ:LPTX)
Today, HC Wainwright initiated coverage on NASDAQ:LPTX – Leap Therapeutics (NASDAQ:LPTX) with a Buy with a price target of $12.50.
Some recent analyst ratings include
- 4/12/2018-HC Wainwright initiated coverage with a Buy rating.
- 3/7/2017-Ladenburg Thalmann initiated coverage with a Buy rating.
- 3/1/2017-Citigroup initiated coverage with a Market Perform rating.
- 2/28/2017-Raymond James Financial initiated coverage with a Outperform rating.
Recent Insider Trading Activity For NASDAQ:LPTX – Leap Therapeutics (NASDAQ:LPTX)
NASDAQ:LPTX – Leap Therapeutics (NASDAQ:LPTX) has insider ownership of 58.70% and institutional ownership of 2.77%.
- On 11/14/2017 Augustine Lawlor, COO, bought 1,057,769 with an average share price of $6.09 per share and the total transaction amounting to $6,441,813.21.
Recent Trading Activity for NASDAQ:LPTX – Leap Therapeutics (NASDAQ:LPTX)
Shares of NASDAQ:LPTX – Leap Therapeutics closed the previous trading session at 9.70 down -0.01 0.11% with shares trading hands.